First in vivo evaluation of particulate nasal dry powder vaccine formulations containing ovalbumin in mice
- 1 February 2015
- journal article
- research article
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 479 (2) , 408-415
Abstract
No abstract availableKeywords
Funding Information
- Deutsche Forschungsgemeinschaft
- Wissenschaftlerinnenförderung
This publication has 36 references indexed in Scilit:
- Opportunities and challenges of the pulmonary route for vaccinationExpert Opinion on Drug Delivery, 2011
- Vaccine delivery: a matter of size, geometry, kinetics and molecular patternsNature Reviews Immunology, 2010
- Vaccination Strategies to Promote Mucosal Antibody ResponsesImmunity, 2010
- Nanotechnology solutions for mucosal immunizationAdvanced Drug Delivery Reviews, 2010
- Immune response by nasal delivery of hepatitis B surface antigen and codelivery of a CpG ODN in alginate coated chitosan nanoparticlesEuropean Journal of Pharmaceutics and Biopharmaceutics, 2008
- Development of Stable Influenza Vaccine Powder Formulations: Challenges and PossibilitiesPharmaceutical Research, 2008
- Chitosan and trimethyl chitosan chloride (TMC) as adjuvants for inducing immune responses to ovalbumin in mice following nasal administrationJournal of Controlled Release, 2007
- N-Trimethyl chitosan (TMC) nanoparticles loaded with influenza subunit antigen for intranasal vaccination: Biological properties and immunogenicity in a mouse modelVaccine, 2007
- Biodegradable mucoadhesive particulates for nasal and pulmonary antigen and DNA deliveryAdvanced Drug Delivery Reviews, 2005
- Intranasal vaccination against plague, tetanus and diphtheriaAdvanced Drug Delivery Reviews, 2001